Clinical trials: MAFLD

NASH - Nonalcoholic Steatohepatitis

Study Evaluating the Safety, Efficacy and Tolerability of BIO89-100 in Subjects With Biopsy-confirmed Nonalcoholic Steatohepatitis (NASH)

• Completed
• Age: 21 to 75 years
• Phase 2
• Results posted

This is a randomized, double-blind, placebo-controlled study that will evaluate the safety, efficacy, tolerability of BIO89-100 in patients with biopsy-confirmed fibrosis stages F2-F3 NASH.

Trial name

ENLIVEN (NCT04929483)

Testing

BIO89-100

Where

89 sites in United States, Puerto Rico

Volunteers

222 people

Sponsor

89bio, Inc.